| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:XJ02862-S2
CAS:3023355-55-4
Package:10mg;50mg
|
|
| | XJ02862-S2 Basic information |
| Product Name: | XJ02862-S2 | | Synonyms: | XJ02862-S2;1H-Isoindole-1,3(2H)-dione, 2-[(1S)-2-[(2S,4R)-3,4-dihydro-2-methyl-4-(phenylamino)-1(2H)-quinolinyl]-1-methyl-2-oxoethyl]hexahydro- | | CAS: | 3023355-55-4 | | MF: | C27H31N3O3 | | MW: | 445.55 | | EINECS: | | | Product Categories: | | | Mol File: | 3023355-55-4.mol |  |
| | XJ02862-S2 Chemical Properties |
| Boiling point | 703.551±60.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.242±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 3.744±0.40(predicted) |
| | XJ02862-S2 Usage And Synthesis |
| Uses | XJ02862-S2 shows potent FXR agonistic activity. XJ02862-S2 is a promising lead compound for the research of NAFLD[1]. | | in vivo | XJ02862-S2 could ameliorate hypercholesterolemia, hepatic steatosis, hyperglycemia, insulin resistance (IR) in high-fat-diet induced obese (DIO) mice[1]. | | References | [1] Tong Qin, et al. Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease. Eur J Med Chem. 2023 Apr 5;252:115307. DOI:10.1016/j.ejmech.2023.115307 |
| | XJ02862-S2 Preparation Products And Raw materials |
|